Publication
Title
Targeted therapy in combination with chemotherapy in recurrent and/or metastatic head and neck cancer
Author
Abstract
Two epidermal growth factor receptor (EGFR)-targeting strategies are used in recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN): monoclonal antibodies and small-molecule tyrosine kinase inhibitors. Thus far, the monoclonal antibody cetuximab has been studied in most detail. Based on the results of two randomised phase III trials, cetuximab in combination with platinum-based chemotherapy should be considered the new standard first-line regimen for patients with recurrent and/or metastatic disease for whom a platinum-based regimen regimen is considered the best treatment option. Other EGFR-directed monoclonal antibodies are under investigation. The role of EGFR tyrosine kinase inhibitors (TKIs) in SCCHN is less well established and early data on other targeted agents have also been disappointing thus far. Dual pathway inhibition may overcome resistance to single pathway inhibition.
Language
English
Source (journal)
European oncology. - Goring-on-Thames, 2005, currens
Publication
Goring-on-Thames : Touch medical media, 2010
ISSN
1758-3853 [Print]
1758-3861 [Online]
Volume/pages
6:1(2010), p. 43-46
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 21.03.2014
Last edited 02.10.2015
To cite this reference